AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Dacarbazine belongs to a class of medications known as alkylating agents, which work by damaging the DNA of cancer cells, leading to their death. Dacarbazine is a prodrug that undergoes metabolic activation to form reactive intermediates, which then alkylate DNA, causing DNA strand breaks and inhibition of DNA replication and transcription. This ultimately results in cell cycle arrest and apoptosis (programmed cell death) of cancer cells.
Treatment of Melanoma: Dacarbazine is commonly used in the treatment of metastatic melanoma, a type of skin cancer that has spread to other parts of the body. It may be used alone or in combination with other chemotherapy drugs or immunotherapy agents. Dacarbazine helps to shrink tumors, slow down disease progression, and improve survival outcomes in patients with advanced melanoma.
Treatment of Hodgkin's Lymphoma: Dacarbazine is also used as part of combination chemotherapy regimens for the treatment of Hodgkin's lymphoma, a type of cancer that affects the lymphatic system. It may be used in combination with other chemotherapy drugs such as doxorubicin, bleomycin, and vinblastine (ABVD regimen) or as part of salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Soft Tissue Sarcomas: Dacarbazine may be used in the treatment of certain types of soft tissue sarcomas, including leiomyosarcoma, malignant fibrous histiocytoma, and liposarcoma. It may be used alone or in combination with other chemotherapy agents, surgery, or radiation therapy, depending on the specific subtype and stage of soft tissue sarcoma.
Dosage and Administration: Dacarbazine is typically administered intravenously (IV) by a healthcare professional in a hospital or clinic setting. The dosage and schedule of administration depend on factors such as the type of cancer being treated, the patient's overall health, and their response to treatment. Dacarbazine is often given in cycles, with rest periods between doses to allow the body to recover from side effects.
Side Effects: Common side effects of dacarbazine may include nausea, vomiting, diarrhea, loss of appetite, fatigue, weakness, hair loss, and low blood cell counts (anemia, leukopenia, thrombocytopenia). Dacarbazine can also cause infusion reactions, liver toxicity, and increased risk of infection due to bone marrow suppression. Patients should be monitored closely for side effects during dacarbazine therapy, and supportive care measures may be implemented to manage symptoms and complications.
Long-term Effects: Dacarbazine treatment may be associated with long-term effects such as increased risk of secondary malignancies, particularly leukemia and myelodysplastic syndromes (MDS), as well as infertility and reproductive toxicities. Patients should be informed about the potential long-term effects of dacarbazine therapy and may require long-term monitoring for late-onset complications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.7 | 0.6 | 3.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.3 | 1.2 | 0.08 |
| Allergies | 2.4 | 2.1 | 0.14 |
| Allergy to milk products | 1.4 | 0.6 | 1.33 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 2.5 | 5.6 | -1.24 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.3 | 4.33 |
| Ankylosing spondylitis | 2.2 | 1 | 1.2 |
| Anorexia Nervosa | 1.2 | 3 | -1.5 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 4.3 | 1.9 | 1.26 |
| Atherosclerosis | 1.5 | 1.3 | 0.15 |
| Atrial fibrillation | 2.8 | 1.6 | 0.75 |
| Autism | 5.7 | 5.7 | 0 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.4 | 1.7 | -0.21 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 1.4 | -1.33 |
| Carcinoma | 2.5 | 1.6 | 0.56 |
| Celiac Disease | 2.2 | 2.6 | -0.18 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 3.7 | 3 | 0.23 |
| Chronic Kidney Disease | 1.3 | 2.1 | -0.62 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.7 | -0.13 |
| Chronic Urticaria (Hives) | 0.8 | 0.7 | 0.14 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
| Cognitive Function | 1.5 | 1.6 | -0.07 |
| Colorectal Cancer | 4 | 2.2 | 0.82 |
| Constipation | 1 | 0.7 | 0.43 |
| Coronary artery disease | 1.3 | 2.6 | -1 |
| COVID-19 | 4.7 | 7.5 | -0.6 |
| Crohn's Disease | 4.4 | 3.9 | 0.13 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.4 | -1.4 | |
| deep vein thrombosis | 0.6 | 1.4 | -1.33 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 5.9 | 6.2 | -0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.9 | 1.9 | -1.11 |
| Endometriosis | 1.3 | 2 | -0.54 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2 | 0.7 | 1.86 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 2.1 | 1.8 | 0.17 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 2.8 | 0.36 |
| gallstone disease (gsd) | 1.4 | 0.8 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.6 | 0.17 |
| Generalized anxiety disorder | 1.4 | 1.8 | -0.29 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.5 | 0.8 |
| Graves' disease | 1.5 | 2.7 | -0.8 |
| Gulf War Syndrome | 0.9 | 1.2 | -0.33 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.2 | 1.2 | 0.83 |
| Heart Failure | 1.9 | 1.6 | 0.19 |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.1 | 0.6 | 0.83 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.7 | 0.7 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 1.9 | 5.3 | -1.79 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 1.1 | 0.3 | 2.67 |
| IgA nephropathy (IgAN) | 1.2 | 2.9 | -1.42 |
| Inflammatory Bowel Disease | 5.1 | 6.6 | -0.29 |
| Insomnia | 1.9 | 2.4 | -0.26 |
| Intelligence | 0.8 | 0.4 | 1 |
| Intracranial aneurysms | 0.7 | 0.6 | 0.17 |
| Irritable Bowel Syndrome | 3.5 | 3.3 | 0.06 |
| ischemic stroke | 2 | 1.1 | 0.82 |
| Liver Cirrhosis | 5.5 | 2.8 | 0.96 |
| Long COVID | 5.3 | 5.5 | -0.04 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 0.4 | -0.33 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 1.1 | 1.2 | -0.09 |
| ME/CFS without IBS | 1.2 | 0.6 | 1 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1 | 0.5 | 1 |
| Metabolic Syndrome | 4.3 | 5.3 | -0.23 |
| Mood Disorders | 6.1 | 5.3 | 0.15 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 3.7 | 4.2 | -0.14 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.2 | -6.33 |
| Neuropathy (all types) | 0.7 | 0.6 | 0.17 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 3.4 | 0.09 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 5.1 | 5.3 | -0.04 |
| obsessive-compulsive disorder | 2.2 | 2.4 | -0.09 |
| Osteoarthritis | 1.7 | 1.2 | 0.42 |
| Osteoporosis | 1.9 | 0.7 | 1.71 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4.6 | 5.5 | -0.2 |
| Polycystic ovary syndrome | 3.4 | 3.1 | 0.1 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.6 | 0.8 | -0.33 |
| Primary sclerosing cholangitis | 1.1 | 1.1 | 0 |
| Psoriasis | 1.9 | 1.9 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 3.3 | 0.45 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 4.6 | 2.6 | 0.77 |
| scoliosis | 0.3 | 1 | -2.33 |
| Sjögren syndrome | 1.4 | 1.2 | 0.17 |
| Sleep Apnea | 1.3 | 1.8 | -0.38 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.4 | 2.5 |
| Stress / posttraumatic stress disorder | 1.3 | 2 | -0.54 |
| Systemic Lupus Erythematosus | 2.8 | 1.8 | 0.56 |
| Tic Disorder | 1 | 0.9 | 0.11 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.6 | 3.3 | -0.27 |
| Type 2 Diabetes | 5.1 | 4.2 | 0.21 |
| Ulcerative colitis | 3.2 | 4.6 | -0.44 |
| Unhealthy Ageing | 2.9 | 1.8 | 0.61 |
| Vitiligo | 1.8 | 1.1 | 0.64 |
